Raging Bull? SP500 Levels, Refreshed

Takeaway: Alongside this no-volume raging bull comes an increasing amount of mean reversion risk – so just know that.

If all you do into year-end is buy-the-damn-bubble #BTDB on dips, you’ll probably keep getting paid. But alongside this no-volume raging bull comes an increasing amount of mean reversion risk – so just know that.


What was best about today’s rip to new all-time highs was that it came on what’s really been driving the US stock market for the better part of the last 10-11 months. The ISM report’s growth components once again surprised on the upside (NOV's New Orders = 63.6 and Employment of 56.5 were the best monthly readings, respectively, of 2013).


Rates UP, Dollar UP today – and you know I like that. But the Fed doesn’t. Makes them look silly for not tapering (that’s what not being data dependent gets you into – a good ole politicized pickle!). So prepare for more @FederalReserve storytelling as they continue to pander to the Bond Bull Lobby @PIMCO.


Across our core risk management durations, here are the lines that matter to me most:


  1. Immediate-term TRADE overbought = 1816
  2. Immediate-term TRADE support = 1782
  3. Intermediate-term TREND support = 1726


In other words, now you have 90 $SPY handles of mean reversion downside, or -5%, to my 1726 @Hedgeye TREND line. And every time it feels like we’re not going to correct, that’s about how much we’ve corrected (3 separate 5% corrections in 2013 YTD).


So keep your eyes on your fries and keep moving out there,



Keith R. McCullough
Chief Executive Officer


Raging Bull? SP500 Levels, Refreshed - SPX

GOLD: A Deep Dive on What’s Next with a Top Commodities Strategist

“If you saved in gold over the past 20 to 25 years rather than any currency anywhere in the world, gold has outperformed all these currencies,” says Stefan Wieler, Vice President of Goldmoney in this edition of Real Conversations.

read more

Exact Sciences Up +24% This Week... What's Next? | $EXAS

We remain long Exact Sciences in the Hedgeye Healthcare Position Monitor.

read more

Inside the Atlanta Fed's Flawed GDP Tracker

"The Atlanta Fed’s GDPNowcast model, while useful at amalgamating investor consensus on one singular GDP estimate for any given quarter, is certainly not the end-all-be-all of forecasting U.S. GDP," writes Hedgeye Senior Macro analyst Darius Dale.

read more

Cartoon of the Day: Acrophobia

"Most people who are making a ton of money right now are focused on growth companies seeing accelerations," Hedgeye CEO Keith McCullough wrote in today's Early Look. "That’s what happens in Quad 1."

read more

People's Bank of China Spins China’s Bad-Loan Data

PBoC Deputy Governor Yi says China's non-performing loan problem has “pretty much stabilized." "Yi is spinning. China’s bad-debt problem remains serious," write Benn Steil and Emma Smith, Council on Foreign Relations.

read more

UnderArmour: 'I Am Much More Bearish Than I Was 3 Hours Ago'

“The consumer has a short memory.” Yes, Plank actually said this," writes Hedgeye Retail analyst Brian McGough. "Last time I heard such arrogance was Ron Johnson."

read more

Buffalo Wild Wings: Complacency & Lack of Leadership (by Howard Penney)

"Buffalo Wild Wings has been plagued by complacency and a continued lack of adequate leadership," writes Hedgeye Restaurants analyst Howard Penney.

read more

Todd Jordan on Las Vegas Sands Earnings

"The quarter actually beat lowered expectations. Overall, the mass segment performed well although base mass lagging is a concern," writes Hedgeye Gaming, Lodging & Leisure analyst Todd Jordan on Las Vegas Sands.

read more

An Update on Defense Spending by Lt. Gen Emo Gardner

"Congress' FY17 omnibus appropriation will fully fund the Pentagon's original budget request plus $15B of its $30B supplemental request," writes Hedgeye Potomac Defense Policy analyst Lt. Gen Emerson "Emo" Gardner USMC Ret.

read more

Got Process? Zero Hedge Sells Fear, Not Truth

Fear sells. Always has. Look no further than Zero Hedge.

read more

REPLAY: Review of $EXAS Earnings Call (A Hedgeye Best Idea Long)

Our Healthcare Team made a monster call to be long EXAS - hear their updated thoughts.

read more

Capital Brief: 5 Things to Watch Right Now In Washington

Here's a quick look at some key issues investors should keep an eye on from Hedgeye's JT Taylor and our team of Washington Policy analysts in D.C.

read more